The FDA has approved imlunestrant for the treatment of patients with ESR1-mutated ER+, HER2- metastatic breast cancer.

BC, AOCNP, explains how ctDNA can inform prognosis, monitor disease progression, and guide treatment decisions in oncology.

Caleb Raine, PA-C explains what BCMA is and why it is a common bispecific antibody target in multiple myeloma.

The NCCN has added revumenib (Revuforj) to its guidelines for the treatment of patients with relapsed or refractory acute ...

Oncology Nursing News connects oncology nurses and APPs with updates on therapy advances, side effect management, and patient ...

Subcutaneous pembrolizumab has been approved across all indications, cutting chair and administration times with a median ...

When treating patients with bladder cancer using gemcitabine intravesical system, regular AE monitoring is necessary, said ...

At SOHO 2025, Lorenzo Falchi, MD, highlighted the critical role of nurses in monitoring and educating patients on toxicities ...

In an interview with Oncology Nursing News, Kirschner, who serves as the director of program development at the Cancer ...

Pediatric oncology is defined not only by advanced treatments but also by the depth of support provided to patients and families, according to Scott C. Borinstein, MD, PhD, medical director of ...

Explore stories of oncology nurses who forge connections with patients, transforming challenges into triumphs in cancer care.

C, OCN, discusses how patient comorbidities and adverse effect profiles guide CDK4/6 inhibitor choice in the first-line setting.